Primary biliary cirrhosis: specific treatment.

Area of Science:

• Hepatology
• Immunology
• Gastroenterology

Background:

• Primary biliary cholangitis (PBC) is a chronic liver disease with limited treatment options.
• Current therapies do not definitively delay liver transplantation or reduce mortality in PBC patients.
• Uncertainty exists regarding the optimal therapeutic approach for managing PBC.

Purpose of the Study:

• To review the evidence for various therapeutic agents in primary biliary cholangitis.
• To identify the safest and most effective treatment options for PBC based on clinical trial data.
• To guide recommendations for specific therapies in PBC management.

Main Methods:

• Review of scientific literature and clinical trial data for agents used in PBC treatment.
• Evaluation of efficacy, safety, and toxicity profiles of ursodiol, azathioprine, cyclosporine, and methotrexate.
• Assessment of evidence quality from randomized clinical trials and anecdotal studies.

Main Results:

• Ursodiol demonstrates the strongest scientific proof of efficacy with the lowest toxicity among evaluated agents.
• Azathioprine and methotrexate show promise, with established safety profiles from extensive clinical trials.
• Cyclosporine may be considered for patients refractory to other treatments.

Conclusions:

• Ursodiol is recommended as the safest and potentially most effective therapy for PBC based on current evidence.
• Azathioprine and methotrexate serve as viable alternatives for patients unresponsive or intolerant to ursodiol.
• Further well-designed, large-scale, long-term clinical trials are needed to discover highly effective PBC treatments.